The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethyl-, 1,2 diethyl-, and 1-[ethan-1′ ol]-2-methyl-3-hydroxypyridin-4-one in the rat
- 30 April 1996
- journal article
- Published by Elsevier BV in Toxicology
- Vol. 108 (3), 191-199
- https://doi.org/10.1016/0300-483x(95)03301-u
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Evidence for energy-dependent transport of aluminum out of brain extracellular fluidToxicology, 1995
- Aluminum Toxicity in Patients with Chronic Renal FailureTherapeutic Drug Monitoring, 1993
- Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potentialJournal of Medicinal Chemistry, 1993
- Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseasesIndian Journal of Pediatrics, 1993
- 4-trimethylammonium antipyrine: A quaternary ammonium nonradionuclide marker for blood-brain barrier integrity during in vivo microdialysisJournal of Pharmacological and Toxicological Methods, 1992
- A comparison of the iron-clearing properties of 1,2-dimethyl-3- hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamineBlood, 1992
- Dissimilar Aluminum and Gallium Permeation of the Blood‐Brain Barrier Demonstrated by In Vivo MicrodialysisJournal of Neurochemistry, 1992
- Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemiaClinical Pharmacology & Therapeutics, 1991
- Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-oneClinical Pharmacology & Therapeutics, 1990
- REVERSAL OF ALUMINIUM DIALYSIS ENCEPHALOPATHY AFTER DESFERRIOXAMINE TREATMENTThe Lancet, 1981